Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline effect on C-reactive protein and dialysis adequacy in ESRD
IRCT2013120715695N1Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pentoxifylline in end-stage kidney disease (ESKD) and coronary arteriosclerosis, sponsored by Arak University of Medical Sciences. Primary endpoints: Change in C-reactive protein level and Dialysis adequacy. Started Mar 2014; status: completed.
02
Drugs
pentoxifylline
03
Conditions
end-stage kidney disease (ESKD)coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT2013120715695N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013120715695N1.